Mark J. Anderton

2.4k citations

14 papers · 1.1k indexed · 1 hit paper · h-index 9

Co-authors: John Garthwaite Eric Southam Margaret M. Manson Marion L. Williams William P. Steward Andreas J. Gescher Richard D. Verschoyle John H. Lamb
Topics: Bioactive Compounds and Antitumor Agents (2 papers)Advanced Breast Cancer Therapies (2 papers)Synthesis of Indole Derivatives (2 papers)
Cited by: Toxicology Neurology Molecular Biology
Journals: Nature Reviews Drug Discovery Cancer Research Clinical Cancer Research
Partner nations: United Kingdom United States Sweden

In The Last Decade

Mark J. Anderton

14 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of a five-dimensional framework on R&D productivity at AstraZeneca

2018 271 citations Paul Morgan, Dean G. Brown et al. Nature Reviews Drug Discovery profile →

Peers

Countries citing papers authored by Mark J. Anderton

Since Specialization

Citations

This map shows the geographic impact of Mark J. Anderton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Anderton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Anderton more than expected).

Fields of papers citing papers by Mark J. Anderton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Anderton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Anderton. The network helps show where Mark J. Anderton may publish in the future.

Co-authorship network of co-authors of Mark J. Anderton

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Anderton. A scholar is included among the top collaborators of Mark J. Anderton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Anderton. Mark J. Anderton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Abstract 5298: Activity and tolerability of combinations of trastuzumab deruxtecan (T-DXd) with inhibitors of the DNA damage response in preclinical models 2022 ·Cancer Research ·Yann Wallez,Theresa A. Proia,(unknown),Ankur Karmokar,Zena Wilson,Suzanne J. Randle,Mark J. Anderton,Stephen T. Durant,Elisabetta Leo,Alan Lau,Mark J. O’Connor,Jerome T. Mettetal	1
2	Abstract 1374: The novel PARP1-selective inhibitor AZD5305 has reduced hematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models 2021 ·Cancer Research ·Sonja J. Gill,Ruth S. MacDonald,Carmen Pin,(unknown),(unknown),Gareth Maglennon,Andy Pike,(unknown),(unknown),(unknown),(unknown),Daniel Sutton,James B. Atkinson,(unknown),(unknown),Mark J. Anderton	2
3	Impact of a five-dimensional framework on R&D productivity at AstraZenecabreakdown → 2018 ·Nature Reviews Drug Discovery ·Paul Morgan,Dean G. Brown,Simon Lennard,Mark J. Anderton,J. Carl Barrett,Ulf G. Eriksson,Mark Fidock,Bengt Hamrén,Anthony Johnson,Ruth March,James Matcham,Jerome T. Mettetal,David Nicholls,Stefan Platz,Steve Rees,Michael Snowden,Menelas N. Pangalos	271
4	De novo LINE - 1 retrotransposition in HepG2 cells preferentially targets gene poor regions of chromosome 13 2014 ·Genomics ·Pasano Bojang,Mark J. Anderton,Ruth Roberts,Kenneth S. Ramos	5
5	Abstract 3676: Influence of early toxicology assessment on the selection of azd9291 2014 ·Cancer Research ·Mark J. Anderton,Richard A. Ward,(unknown),(unknown),Darren A.E. Cross,(unknown),M. Raymond V. Finlay	1
6	Reprogramming of the HepG2 genome by long interspersed nuclear element‐1 2013 ·Molecular Oncology ·Pasano Bojang,Ruth Roberts,Mark J. Anderton,Kenneth S. Ramos	18
7	Abstract B94: Discovery of and first disclosure of the clinical candidate AZD9291, a potent and selective third-generation EGFR inhibitor of both activating and T790M resistant mutations that spares the wild type form of the receptor. 2013 ·Molecular Cancer Therapeutics ·M. Raymond V. Finlay,Mark J. Anderton,Susan Ashton,Peter Ballard,(unknown),Sam Butterworth,Claudio Chuaqui,Nicola Colclough,Darren A.E. Cross,(unknown),Martine J. Mellor,Richard A. Ward,(unknown)	3
8	Epigenetics – relevance to drug safety science 2012 ·Toxicology Research ·Catherine Priestley,Mark J. Anderton,Ann Doherty,Paul Duffy,Howard R. Mellor,Helen Powell,Ruth Roberts	8
9	Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors 2011 ·Toxicologic Pathology ·Mark J. Anderton,Howard R. Mellor,Alex Bell,C Sadler,Martin Pass,Steve Powell,(unknown),Ruth Roberts,Annabelle Heier	211
10	PHYSIOLOGICAL MODELING OF FORMULATED AND CRYSTALLINE 3,3′-DIINDOLYLMETHANE PHARMACOKINETICS FOLLOWING ORAL ADMINISTRATION IN MICE 2004 ·Drug Metabolism and Disposition ·Mark J. Anderton,Margaret M. Manson,Richard D. Verschoyle,Andreas J. Gescher,William P. Steward,Marion L. Williams,Donald E. Mager	106
11	Pharmacokinetics and Tissue Disposition of Indole-3-carbinol and Its Acid Condensation Products after Oral Administration to Mice 2004 ·Clinical Cancer Research ·Mark J. Anderton,Margaret M. Manson,Richard D. Verschoyle,Andreas J. Gescher,John H. Lamb,Peter B. Farmer,William P. Steward,Marion L. Williams	185
12	Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma 2003 ·Journal of Chromatography B ·Mark J. Anderton,Rebekah Jukes,John H. Lamb,Margaret M. Manson,Andreas J. Gescher,William P. Steward,Marion L. Williams	45
13	Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase Cα, src-tyrosine kinase and extracellular signal-regulated kinase but not phospholipase C 2002 ·Molecular Brain Research ·(unknown),Mark J. Anderton,Nigel M. Hooper,Anthony J. Turner,Peter F. T. Vaughan	48
14	A Kainate Receptor Linked to Nitric Oxide Synthesis from Arginine 1989 ·Journal of Neurochemistry ·John Garthwaite,Eric Southam,Mark J. Anderton	186

About Mark J. Anderton

Mark J. Anderton is a scholar working on Toxicology, Oncology and Immunology and Allergy, having authored 14 papers that have together received 1.1k indexed citations. Recurring topics across this work include Bioactive Compounds and Antitumor Agents (2 papers), Advanced Breast Cancer Therapies (2 papers) and Synthesis of Indole Derivatives (2 papers). The work is most often cited by research in Toxicology (74 citations), Neurology (72 citations) and Molecular Biology (558 citations). Mark J. Anderton has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include John Garthwaite, Eric Southam, Margaret M. Manson, Marion L. Williams, William P. Steward, Andreas J. Gescher, Richard D. Verschoyle, John H. Lamb, Howard R. Mellor and Steve Powell. Their work appears in journals such as Nature Reviews Drug Discovery, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact